Day: October 29, 2021

October 29, 2021THIRD QUARTER 2021Continuing recovery in capacity generates strong revenue growth andpositive operating results for the first time since the start of the Covid-19 crisis,Adjusted operating free cash flow positive at 278 million eurosthanks to EBITDA contributionThird quarter:Revenue at 4,567 million euros, up 2,043 million compared to last year Operating result at 132 million euros, up 1,178 million euros compared to last year EBITDA improved to 796 million euros, an increase of 1,238 million euros compared to last year Strong performance of Transavia with an operational result of 105 million euros Net income at -192 million euros, up 1,473 million euros compared to last year Net debt at 8.1 billion euros, down by 2.9 billion euros compared to end of 2020 thanks to the first set of capital strengthening measuresOUTLOOK After...

Publication on October 29, 2021, before market openingRegulated information – Press releaseEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS ANNOUNCES THE APPOINTMENT OF VEERLE DE WIT AS CFO OF THE COMPANY EVS Broadcast Equipment, leading provider of live video production systems, today announces the appointment of Veerle De Wit as CFO of the company. Mrs. Veerle De Wit currently serves as CFO for the technology services company NTT Belgium (€320 million revenue business). Previously, she held various finance and management positions at IBM where she started her career in 1998 and served as Chief Financial Officer from 2012 to 2016. She holds a Master’s degree in Finance from Lessius Hogeschool Antwerpen. Mrs. Veerle De Wit will start as CFO of EVS on November 2nd, 2021. Mrs. Ingrid Rogy,...

MIAMI BEACH, Fla., Oct. 29, 2021 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (“AirSculpt”), an industry leader and national provider of body contouring procedures delivering a premium consumer experience under its brand, Elite Body Sculpture, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $11.00 per share (comprising 2,173,913 shares of common stock to be issued by the Company and 4,826,087 shares of common stock to be sold by certain selling stockholders). In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock from certain selling stockholders at the initial public offering price, less underwriting discounts and commissions. The common stock is expected to begin trading on...

BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines and aiming to become the world’s foremost intracellular therapeutics company, today announced the pricing of its upsized initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share. All shares are being offered by Entrada. The gross proceeds to Entrada from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $181.5 million. The shares are expected to begin trading on The Nasdaq Global Market under the ticker symbol “TRDA” on October 29, 2021. The offering is expected to close...

WOBURN, MA. , Oct. 28, 2021 (GLOBE NEWSWIRE) — Biofrontera Inc. (“Biofrontera” or the “Company”) (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the pricing of its underwritten initial public offering of 3,600,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $5.00. The warrants have an exercise price of $5.00 per share and are exercisable for a period of five years after the issuance date. All units are being offered by Biofrontera Inc. In addition, Biofrontera has granted the underwriters a 30-day option to purchase an additional 540,000 shares of its common stock and/or warrants to purchase up to an additional 540,000 of its common stock,...

MONTREAL, Oct. 28, 2021 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) announces that the Luxembourg Administrative Court has confirmed on appeal the previously-announced decision of the Luxembourg Administrative Tribunal to the effect that one of Dorel’s wholly-owned subsidiaries owes €54.6 million (euros) in tax (US$64.2 million) including interest. As a result of the judgment of the Luxembourg Administrative Court, Dorel must pay a one-time remaining cash balance of €38.6 million (euros) (US$45.4 million) to the Luxembourg tax authorities. Dorel expects that the judgment will have an effect of US$1.90 on earnings per share in its financial statements for the third quarter ended September 30, 2021. Dorel will release its results for the third quarter ended September 30, 2021 on November 5, 2021. As previously announced,...

VANCOUVER, British Columbia, Oct. 28, 2021 (GLOBE NEWSWIRE) — Major Precious Metals Corp. (“Major Precious Metals” or the “Company”) (NEO:SIZE | OTC:SIZYF | FRANKFURT:3EZ), a Canadian exploration and mining company that has recently completed its Phase 1 diamond drilling program on its Skaergaard Project in eastern Greenland, is pleased to announce that it has entered into a definitive convertible security funding agreement (“Agreement”) with L1 Capital Global Opportunities Master Fund (“Investor“), a Cayman based investment fund, part of the L1 Capital Group. The funding will come in the form of up to CAD $6 million face-value (“Face Value“) convertible debentures (the “Convertible Debentures“) . The Company will receive net proceeds of up to CAD $5.4 million from the Convertible Debenture issuance,...

EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it priced an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of $25.00 per share. The gross proceeds from the offering are expected to be approximately $118.8 million before deducting underwriting discounts and commissions and other offering expenses. In addition, 4D Molecular Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by 4D Molecular Therapeutics. The offering...